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Abstract
Hypertension-induced structural remodeling of the left atrium (LA) has been
suggested to involve the renin–angiotensin system. This study investigated
whether treatment with an angiotensin receptor blocker, candesartan, regresses
atrial remodeling in spontaneously hypertensive rats (SHR). Effects of treat-
ment with candesartan were compared to treatment with a nonspecific vaso-
dilatator, hydralazine. Thirty to 32-week-old adult male SHR were either
untreated (n = 15) or received one of either candesartan cilexetil (n = 9;
3 mg/kg/day) or hydralazine (n = 10; 14 mg/kg/day) via their drinking water
for 14 weeks prior to experiments. Untreated age- and sex-matched Wistar-
Kyoto rats (WKY; n = 13) represented a normotensive control group.
Untreated SHR were hypertensive, with left ventricular hypertrophy (LVH)
compared to WKY, but there were no differences in systolic pressures in
excised, perfused hearts. LA from SHR were hypertrophied and showed
increased fibrosis compared to those from WKY, but there was no change in
connexin-43 expression or phosphorylation. Treatment with candesartan
reduced systolic tail artery pressures of conscious SHR below those of normo-
tensive WKY and caused regression of both LVH and LA hypertrophy.
Although hydralazine reduced SHR arterial pressures to those of WKY and
led to regression of LA hypertrophy, it had no significant effect on LVH.
Notably, LA fibrosis was unaffected by treatment with either agent. These data
show that candesartan, at a dose sufficient to reduce blood pressure and LVH,
did not cause regression of LA fibrosis in hypertensive rats. On the other
hand, the data also suggest that normalization of arterial pressure can lead to
the regression of LA hypertrophy.
Introduction
It has been suggested that structural changes to the atria
as a result of an underlying pathology, termed ‘atrial
remodeling’, predispose the heart to atrial fibrillation
(AF) (Casaclang-Verzosa et al. 2008; Benjamin et al.
2009). Dilatation and enlargement of the left atrium
(LA), together with left ventricular hypertrophy (LVH),
are considered to be good epidemiological indicators of
the risk of AF in patients (Vaziri et al. 1994; Tsang et al.
2002b). It is thought that atrial enlargement, interstitial
fibrosis, and remodeling of gap junctions of the
myocardium, by establishing paths of sufficient length
and interfering with normal conduction, contribute to a
pro-arrhythmic substrate favouring reentry (Spach and
Boineau 1997; Nattel 2002; Severs et al. 2008). Evidence
from animal models involving chronic rapid pacing of
the atria indicates that the existence of AF itself leads to
atrial structural remodeling stabilizing the arrhythmia
(‘AF begets AF’) (Wijffels et al. 1995; Ausma et al. 1997;
Schotten et al. 2003). However, the majority of patients
with AF (>70%) have some form of preexisting structural
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heart disease (e.g., heart failure, valve dysfunction, and
hypertension) and it is supposed that these pathologies
give rise to the pro-arrhythmic substrate in which AF is
initiated (Casaclang-Verzosa et al. 2008; Benjamin et al.
2009). The most prevalent independent risk factor for AF
is the existence of systemic hypertension and there is a
clear relationship between arterial blood pressure, LVH,
and LA enlargement (Benjamin et al. 1994; Vaziri et al.
1995). Data from animal models of systemic hypertension
have not only strengthened the case for elevated arterial
pressure as a cause of atrial remodeling but also provide
further evidence supporting an association between atrial
enlargement, interstitial fibrosis, and susceptibility to AF
(Kistler et al. 2006; Choisy et al. 2007).
The mechanisms linking hypertension to atrial remod-
eling remain unclear but it has been proposed that
chronically elevated ventricular afterload results in hemo-
dynamic overload of the left atrium, presumably leading
to the activation of stretch-induced signaling pathways in
the atrial wall (Vaziri et al. 1995; Tsang et al. 2002a;
Casaclang-Verzosa et al. 2008). Activation of the renin–
angiotensin–aldosterone system (RAAS) has also been
suggested to contribute to atrial remodeling (Healey et al.
2005b). In addition to its vasopressor action, angiotensin-
II, acting via AT1 receptors, stimulates cardiac myocyte
hypertrophy, changes in myocardial expression of the
gap junction protein, connexin-43, and synthesis of colla-
gen by cardiac fibroblasts (Sadoshima and Izumo 1993;
Brilla et al. 1994; Tsai et al. 2008b; Adam et al. 2010).
Infusion of experimental animals with angiotensin-II leads
to atrial remodeling involving atrial dilatation and
interstitial fibrosis (Sun et al. 1997; Tsai et al. 2008b; Yagi
et al. 2010). There has therefore been considerable interest
in whether drugs targetted to the RAAS, such as angioten-
sin-converting enzyme (ACE) inhibitors and angiotensin
receptor blockers (ARB), reduce the incidence of AF
or its recurrence in at-risk patients (Healey et al. 2005a;
Schneider et al. 2010; Galzerano et al. 2012). A number
of studies in animal models have demonstrated the
effectiveness of treatment with ACE inhibitors and ARB
in the inhibition of atrial remodeling associated with
the long-term infusion of angiotensin-II (Tsai et al.
2008b), with atrial fibrillation (Kumagai et al. 2003; Anne
et al. 2007; Li et al. 2007; Tsai et al. 2008a; Liu et al.
2010) and with heart failure (Li et al. 2001; Shimano
et al. 2008). However, it is striking that there are rela-
tively few if any data on the effects of RAAS inhibition
on atrial remodeling in animal models of hypertension.
This study was conducted in order to examine the
effectiveness of treatment with candesartan, in compari-
son with the nonspecific vasodilator hydralazine, in the
regression of atrial remodeling in spontaneously hyperten-
sive rat hearts.
Materials and Methods
Animals and drug administration
All procedures were conducted in accordance with the
Animals (Scientific Procedures) Act 1986 of the United
Kingdom and were approved by the University of Bristol
Ethical Review Committee. Adult male spontaneously
hypertensive rats (SHR) of 30–32 weeks of age were
assigned to either control group (SHR control, n = 15) or
to receive one of either hydralazine (SHR hydra, 14 mg/
kg/day, n = 10) or candesartan cilexetil (SHR can, 3 mg/
kg/day, n = 9) via their drinking water for 14 weeks prior
to experiments. This dosage regime for hydralazine has
previously been shown to be effective in reducing systolic
arterial pressure in SHR (Kohya et al. 1995; Tsotetsi et al.
2001). The dosage regimen for candesartan cilexetil was
selected on the basis of preliminary experiments to be
sufficient to reduce systolic arterial pressure in SHR to or
below the systolic arterial pressure of Wistar-Kyoto nor-
motensive controls (WKY; data not shown). Animals were
44–46 weeks of age at the time of experiments, corre-
sponding to an age at which significant remodeling of the
left atrium and increased susceptibility to atrial tachyar-
rhythmia had previously been established to occur in
SHR hearts (Choisy et al. 2007). SHR weighed 354  8 g
at the time of experiments and body weight was unaf-
fected by drug treatment (SHR hydra: 357  3 g; SHR
can: 323  14 g). Age- and sex-matched WKY normo-
tensive controls (n = 13) received control treatment.
WKY weighed 475  13 g at the time of experiments
(P < 0.0001 vs. untreated SHR, Bonferroni multiple com-
parisons post hoc test). Systolic pressure in the tail artery
was measured in conscious animals during the week prior
to experiments by tail cuff plethysmography (Choisy
et al. 2007). Daily water consumption was monitored in
order to calculate the appropriate concentration of drug
to add to the drinking water in order to achieve the daily
dose. Hydralazine was soluble directly in water. Candesar-
tan cilexetil (Sequoia Research Products, Pangbourne,
U.K.) was dissolved to ~10 times the final concentration
in a vehicle of polyethylene glycol 400 (10% v/v), ethanol
(5% v/v), cremophor EL (2% v/v), and tap water (83%
v/v) and the pH was adjusted to 9.0 with 0.5 mol/L
Na2CO3 prior to dilution to the final concentration in
tap water, according to Seltzer et al. (2004). SHR (n = 7)
and WKY rats (n = 5) were treated with vehicle alone via
the drinking water but since there was no significant dif-
ference in any of the measured parameters (e.g., tail
artery pressure, left ventricular weight/heart weight ratio)
between vehicle-treated and untreated age- and sex-
matched SHR and WKY rats, the data were combined
into an SHR control group and a WKY control group.
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Whole heart perfusion
On the day of experimentation, body weight was recorded
prior to sodium pentobarbital general anesthesia (i.p. 60–
80 mg/kg). Hearts were isolated from the rats under gen-
eral anesthesia, mounted on a whole heart perfusion
apparatus and perfused retrogradely via the aorta with a
Krebs’ Henseleit solution (in mmol/l; 118.5 NaCl, 25.0
NaHCO3, 3.0 KCl, 1.2 MgSO4.7H2O, 1.2 KH2PO4, 2.5
CaCl2, 11.1 D-glucose at 37°C) gassed with 95% O2/5%
CO2. As described previously, after 20 min of Langendorff
perfusion, a cannula was inserted into the left atrium and
orthograde perfusion established in the so-called “working
heart” mode with the preload and after-load set to,
respectively, 13 and 62 mmHg (Choisy et al. 2007). The
aortic pressure, atrial pressure, and electrocardiogram
(ECG) were recorded using the PowerLab 8/SP data acqui-
sition system and Chart software version 5 (AD Instruments
Ltd, Oxford, U.K.). Atrial effective period (AERP) and con-
duction velocity (CV) were measured by the recording of
bipolar electrograms from the epicardial surface of the left
atrium using a 5 9 5 electrode array as described
previously (Kim et al. 2011, 2012). The inducibility of
atrial tachyarrhythmias was examined by 5 sec of burst
pacing at cycle lengths of <10 msec (Kim et al. 2011, 2012).
At the end of experiments, hearts were removed from the
perfusion apparatus, dissected, and wet heart weight, left
atrial weight, and left ventricular weight recorded. Left atria
were embedded in Tissue Tek OCT (Sakura Finetek
Europe B.V., Alphen aan den Rijn, Netherlands) and snap
frozen in preparation for histological analysis.
Histology and immunocytochemistry
Cryo-sections (10 lm) of left atrial tissue were prepared
as described previously (Jones et al. 2004). Frozen sec-
tions were fixed using 4% paraformaldehyde for 2 min
and washed with PBS. Sections were dehydrated using an
increasing ethanol series (70%, 85%, and 95% at 20°C).
For the histological analysis of fibrosis, fixed sections were
stained with Masson’s trichrome, digitized images
obtained, and the blue pixel content measured relative to
the total tissue area using Adobe Photoshop CS2. A total
connexin-43 antibody (MAB 3068, Chemicon Interna-
tional Inc., Temecula, CA) and a phospho-connexin-43
(connexin-43P) antibody (3511S, Cell Signaling Technol-
ogy, Beverly, MA) specific to phosphorylation at serine
368 (Solan et al. 2003) were used. AlexaFluor488-conju-
gated anti-mouse IgG1 secondary (A21121, Invitrogen,
Paisley, U.K.) were applied at 1 lg/mL. Using methods
that we have reported previously (Kim et al. 2011), con-
focal images were collected using a LSM-510 laser scan-
ning microscope using the same settings (i.e., objective
lens, laser power, photomultiplier gain, and pixel size) for
each image (Carl Zeiss Ltd, Cambridge, U.K.). Images of
equal area (95.5 9 88.9 lm) were selected at random
from sections (a single image per section) from control
WKY (WKY, n = 8 sections from four rats), control SHR
(SHR control, n = 8–9 sections from four rats), candesar-
tan-treated SHR (SHR can, n = 8–9 sections from three
rats), and hydralazine-treated SHR (SHR hydra, n = 8
sections from three rats) tissue sections and connexin-43-
specific fluorescent staining quantified using ImageJ
(v1.48, NIH).
Statistics
Data are presented as mean  SEM. Student’s t-test and
one-way ANOVA with Bonferroni multiple comparisons
post hoc tests were performed, as appropriate, using
Prism 5.03 (GraphPad Software Inc, San Diego, CA).
P < 0.05 was considered statistically significant.
Results
Systolic tail artery pressures were significantly higher in
conscious spontaneously hypertensive rats of 44–46 weeks
of age compared with those from age-matched WKY nor-
motensive controls (Fig. 1). Prior treatment of the hyper-
tensive rats with oral hydralazine for 14 weeks
significantly reduced tail artery pressures, effectively to
the same level as normotensive controls (Fig. 1). Arterial
pressures in hypertensive rats were also significantly
reduced by treatment with oral candesartan for the same
period of time, although in this case to a value signifi-
cantly less than the systolic pressure of normotensive ani-
mals (Fig. 1).
The heart rate in sinus rhythm was slightly, although
not significantly, greater in excised perfused hearts from
hypertensive rats (SHR) compared with hearts from nor-
motensive WKY controls (Fig. 2A). Pacemaking activity
by the sino-atrial node has been suggested to be remod-
eled in SHR hearts (Heaton et al. 2006; Choisy et al.
2007). Treatment with neither of the antihypertensive
agents had any significant effect on heart rate in sponta-
neously hypertensive rat hearts (Fig. 2A). There were no
significant differences between excised perfused SHR and
WKY hearts in aortic diastolic (Fig. 2B) or systolic
(Fig. 2C) pressures, indicating that ventricular contractil-
ity was not impaired in hearts from hypertensive rats.
Although mean diastolic pressures were slightly greater in
hearts from drug-treated SHR compared with vehicle-
treated SHR hearts, this was not statistically significant
(Fig. 2B). Atrial effective refractory period (AERP) and
conduction velocity (CV) in perfused SHR hearts were
not significantly different to perfused WKY hearts
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(Fig. 3A and B), consistent with previous reports (Choisy
et al. 2007; Lau et al. 2013). Although mean CV in hearts
from antihypertensive-treated SHR were lower than in
hearts from untreated hypertensive rats, this was not sta-
tistically significant (Fig. 3B).
Hearts from hypertensive rats showed significant left
ventricular hypertrophy (LVH) compared with hearts
from the normotensive WKY controls, the mean left ven-
tricular weight/body weight (LVW/BW) ratio of SHR
hearts being 60% greater than that of WKY hearts
(Fig. 4A). Reduction of arterial pressure in SHR to nor-
motensive levels with hydralazine did not lead to signifi-
cant regression of the LVH (Fig. 4A). In contrast,
treatment of hypertensive rats with candesartan effectively
reduced the LVW/BW ratio to the same level as in hearts
from age-matched normotensive animals (Fig. 4A). This
indicates that angiotensin-II type 1 (AT1) receptor block-
ade, but not normalization of systolic arterial pressure,
resulted in regression of LVH. In addition to LVH, hyper-
tension was also associated with left atrial hypertrophy
(LAH) as the left atrial weight/body weight (LAW/BW)
ratio of SHR hearts was approximately 20% greater than
that of hearts from WKY normotensive controls (Fig. 4B).
In contrast to the effects on the LVH, treatment of SHR
with either candesartan or hydralazine reduced LAW/BW
ratios to values not significantly different from WKY
(Fig. 4B).
Left atrial sections from SHR hearts showed marked
interstitial fibrosis compared with sections from normo-
tensive control hearts (Fig. 5A). The cell edges and inter-
calated disks could not reliably be identified in these
sections and it was not possible, therefore, to assess
whether the reduction of left atrial hypertrophy on treat-
ment with the antihypertensive agents reported in Fig-
ure 4 was associated with a reduction in cell size.
Nevertheless, treatment with neither hydralazine nor can-
desartan resulted in regression of fibrosis in the left atria
of spontaneously hypertensive rat hearts (Fig. 5B). Since
changes in connexin-43 expression and in phosphoryla-
tion of connexin-43 at serine 368 have been implicated in
pro-arrhythmic remodeling in heart failure (Burstein
et al. 2009), the remodeling of connexin-43 and the
effects of the antihypertensive drugs were investigated. In
contrast to the fibrosis, there were no detectable differ-
ences in either the pattern or level of expression of conn-
exin-43 and phosphorylated connexin-43 between left
atrial sections from SHR hearts and normotensive WKY
controls (Figs. 6, 7). Curiously, treatment of SHR with
candesartan resulted in significantly greater signal for
Figure 1. Effect of antihypertensive treatment on tail artery blood
pressure in conscious rats. WKY – untreated and vehicle-treated
Wistar Kyoto rats; SHR control – untreated and vehicle-treated
spontaneously hypertensive rats; SHR hydra – hydralazine-treated
SHR; SHR can – candesartan-treated SHR. *P < 0.05;
***P < 0.0001; Bonferroni’s multiple comparisons post hoc test.
A B C
Figure 2. Function of excised perfused working hearts. (A) Heart rate. **P < 0.01, Bonferroni’s multiple comparisons post hoc test. (B) Aortic
diastolic pressure. (C) Aortic systolic pressure.
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phosphorylated connexin-43 compared with control-trea-
ted SHR (Fig. 7B).
Discussion
This study presents novel evidence that the AT1 receptor
antagonist candesartan, at doses sufficient to reduce sys-
tolic arterial pressure and produce regression of left ven-
tricular hypertrophy, does not result in regression of left
atrial fibrosis in spontaneously hypertensive rats. On the
other hand, reduction of arterial pressure by either cande-
sartan or the non-specific vasodilatator, hydralazine, was
associated with regression of left atrial hypertrophy. The
regression of LVH in SHR by treatment with candesartan,
but not by hydralazine, in this study is consistent with a
previous report that the simple lowering of arterial pres-
sure was insufficient to cause regression of LVH but that
AT1 receptor blockade using candesartan had a significant
antihypertrophic effect (Kohya et al. 1995). Moreover, the
data demonstrate that the dose of candesartan used was
effective in the regression of ventricular remodeling, pre-
sumably through actions at ventricular AT1 receptors
(Kohya et al. 1995). Our data demonstrating left atrial
weight/body weight ratios in both candesartan- and
hydralazine-treated SHR that were not significantly differ-
ent to the normotensive WKY control suggest that the
reduction in arterial pressure is sufficient to reverse the
atrial hypertrophy in this model, but not the interstitial
fibrosis, and are consistent with distinct signaling path-
ways underlying the hypertrophic and the fibrotic
responses to hypertension (Burstein and Nattel 2008).
Gap junctions
In contrast to previous reports from models of heart fail-
ure and surgical aortic stenosis in rats, there was no
A
B
Figure 4. Effect of antihypertensive treatment on (A) ventricular
and (B) atrial hypertrophy. *P < 0.05; **P < 0.01; ***P < 0.0001;
Bonferroni’s multiple comparisons post hoc test.
A
B
Figure 3. Atrial electrophysiology of perfused hearts. (A) Atrial
effective refractory period (AERP). (B) Conduction velocity (CV).
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remodeling of connexin-43 expression in the hypertensive
hearts (Rucker-Martin et al. 2006; Kim et al. 2011; Yoon
et al. 2013). It was not possible to determine the localiza-
tion of connexin-43 staining in this study and thus we
were unable to assess whether there was any redistribu-
tion of gap junction proteins to the lateral membranes, as
has been suggested in other models of structural heart
disease (Rucker-Martin et al. 2006; Burstein et al. 2009;
Yoon et al. 2013). There was no change in phosphoryla-
tion at S368 of connexin-43 in the atria from the hyper-
tensive hearts, which is in contrast to a previous report
from a canine model of congestive heart failure (Burstein
et al. 2009). It has been suggested that the expression
ratio of connexin-40 to connexin-43 in the atria is
increased in heart failure (Burstein et al. 2009). However,
since there is relatively little atrial expression of connexin-
40 in the rat heart (Gros et al. 1994; Polontchouk et al.
2001), it was not possible to examine remodeling of this
gap junction protein in hypertension in this study. While
the reason for the difference between the studies remains
unclear, it is possible that the increase in hemodynamic
load on the left atrium in this study was not sufficient to
cause gap junction remodeling. In any case, the lack of
changes in connexin-43 and connexin-43P staining is
consistent with the absence of significant conduction
velocity slowing in the atria of hypertensive hearts com-
pared with normotensive controls.
Treatment of the hypertensive rats with candesartan
unexpectedly resulted in an increased level of staining
with the connexin-43P antibody, suggesting an increase in
A B
Figure 5. Effect of antihypertensive treatment on left atrial fibrosis. (A) Representative photomicrographs of Masson’s trichrome-stained slides
of left atrial tissue. Scale bars represent 100 lm. (B) Mean (SEM) percentage fibrosis in Masson’s trichrome-stained slides of left atrial tissue.
***P < 0.0001; Bonferroni’s multiple comparisons post hoc test, versus WKY.
A
B
Figure 6. Effect of antihypertensive treatment on total connexin-43 expression. (A) Representative sections of anti-connexin-43-stained sections
of left atrial tissue. Scale bars represent 50 lm. (B) Mean (SEM) connexin-43 expression calculated as percentage fluorescence intensity
relative to mean WKY-control level.
2015 | Vol. 3 | Iss. 1 | e12274
Page 6
ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
Candesartan on Atrial Remodeling in Rats S. C. Choisy et al.
the level of atrial connexin-43 phosphorylation at serine
368 in the ARB-treated SHR compared to vehicle-treated
SHR. The mechanism underlying this effect remains
unclear; as serine 368 is a site for protein kinase Ce-
dependent phosphorylation, antagonism of the Gq-cou-
pled AT1 receptor might have been expected to reduce
connexin-43 phosphorylation (Lampe et al. 2000; Ek-
Vitorin et al. 2006; Michel et al. 2013). However, AT1
receptors are present in many tissues and cell types,
including the brain and autonomic nervous system, so
that the effect of treatment with candesartan on atrial
connexin-43 phosphorylation may have been through an
indirect mechanism (Michel et al. 2013). Additionally,
AT1 receptors have been shown to couple to Rac1/STAT3
signaling pathways regulating gene expression and protein
synthesis in atrial myocytes (Tsai et al. 2008b), so that
the effect of candesartan in this study may have been
through a change in the expression of proteins regulating
connexin-43 phosphorylation.
Atrial fibrosis
Our results are in contrast to a previous study of atrial
remodeling in rats made hypertensive by administration of
the nitric oxide synthase (NOS) inhibitor, nitro-x-L-argi-
nine-methyl-ester (L-NAME) via the drinking water for
8 weeks (Okazaki et al. 2006). Although, as found in this
study, oral treatment with hydralazine was without effect
on atrial fibrosis, treatment with candesartan at a dose
(0.1 mg/kg/day) lower than that used in this study signifi-
cantly reduced the area of interstitial fibrosis (Okazaki
et al. 2006). It is possible that the signaling processes
underlying atrial fibrosis in the NOS inhibition model dif-
fer from those underlying the fibrosis in the atria of SHR,
such that AT1 receptors contributed to the former and not
to the latter remodeling and candesartan coadministration
with L-NAME sufficed to inhibit the development of the
fibrosis. Oral treatment with the ARB, losartan, has also
been shown to be effective in reducing the atrial fibrosis in
a coronary artery ligation model of heart failure in rats
(Yoon et al. 2013). In that study, the administration of lo-
sartan was started from the time of surgery so that the
ARB was able to inhibit the development of fibrosis and
atrial remodeling (Yoon et al. 2013). We have previously
shown that, in contrast to these two studies, fibrosis of the
left atria in spontaneously hypertensive rats is evident as
early as 12–14 weeks of age (Choisy et al. 2007). Thus, our
data suggest that oral treatment with candesartan is not
effective in the regression of the atrial fibrosis induced by
long-term systemic hypertension in rats.
Substrate for arrhythmia
Atrial interstitial fibrosis, and associated conduction abnor-
malities, have previously been suggested to contribute to a
substrate for atrial tachyarrhythmia/atrial fibrillation in
SHR hearts (Choisy et al. 2007; Lau et al. 2013). Therefore,
the effects of candesartan and hydralazine treatment on the
inducibility of atrial tachyarrhythmias following burst pac-
ing would have been of considerable interest. However, in
contrast to previous studies in which atrial tachyarrhyth-
mias could be induced in 83% of hearts (Choisy et al.
2007), in this study it was only possible to induce tachyar-
rhythmias in three of the 15 hearts (20%). The low
A
B
Figure 7. Effect of antihypertensive treatment on phosphorylated connexin-43 (connexin-43P) expression. (A) Representative sections of anti-
connexin-43P-stained sections of left atrial tissue. Scale bars represent 50 lm. (B) Mean (SEM) connexin-43P expression calculated as
percentage fluorescence intensity relative to mean WKY control level. **P < 0.01; Bonferroni’s multiple comparisons post hoc test, versus SHR
control
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inducibility of atrial tachyarrhythmias is likely related to
the small size of the left atria of SHR hearts in this study
(60  3 mg) as compared with our previous study
(98  7 mg, n = 22; P < 0.0001, Student’s unpaired t-test)
and as compared with WKY in this study (67  3 mg,
n = 13). The small size of the atria of SHR hearts in this
study is associated with low body weight as compared with
the previous study (354  8 g vs. 456  9 g; P < 0.0001,
Student’s unpaired t-test). Thus, it seems likely that the size
of the substrate, in addition to the existence of fibrosis and
conduction abnormalities, plays an important role in the
inducibility of tachyarrhythmia. Moreover, as a conse-
quence of the low number of SHR hearts in which atrial
tachyarrhythmias could be induced, this study was not
sufficiently statistically powered to assess the effect of
the antihypertensive treatment on the inducibility of
arrhythmias.
Nevertheless, our findings may provide some insight
into the lack of effectiveness of ACE inhibitors and ARB
in the reduction of AF incidence in post hoc analyses of
trials in patients with primary hypertension (Healey et al.
2005b; Schneider et al. 2010). While the Losartan Inter-
vention For Endpoint Reduction in Hypertension (LIFE)
and Valsartan Antihypertensive Long-term Use Evalua-
tion (VALUE) studies have suggested a reduction in new
onset AF with AT1 receptor blockade (Wachtell et al.
2005; Schmieder et al. 2008), other trials involving ACE
inhibitors (e.g., Hansson et al. 1999a,b; Salehian et al.
2007) or ARB (e.g., Yusuf et al. 2008) have not revealed
any benefit of RAAS inhibition in patients with primary
hypertension. A meta-analysis of these trials indicates no
overall benefit of ACE inhibitors or ARB in the reduction
of AF in hypertensive patients (Schneider et al. 2010).
Our data support the view that while these agents are
effective antihypertensives, they may not be able to
regress the interstitial fibrosis that plays an important
role in the substrate for arrhythmia in hypertension
(Nattel and Opie 2006). A more complete understanding
of the mechanisms underlying atrial remodeling in hyper-
tension is warranted in order to identify novel potential
therapeutic targets for the regression of atrial fibrosis;
studies using animal models of hypertension, such as the
spontaneously hypertensive rat, are likely to be highly
valuable in this regard.
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